Open Access

Serotype epidemiology and multidrug resistance patterns of Salmonella enterica infecting humans in Italy

  • Ilaria Frasson1,
  • Sabrina Bettanello2,
  • Ettore De Canale2,
  • Sara N. Richter1, 2Email author and
  • Giorgio Palù1, 2
Gut Pathogens20168:26

https://doi.org/10.1186/s13099-016-0110-8

Received: 31 March 2016

Accepted: 19 May 2016

Published: 1 June 2016

Abstract

Background

Salmonella enterica is the zoonotic agent most frequently responsible for foodborne infections in humans worldwide. In this work the presence of S. enterica was investigated in 734 unique enteropathogenic isolates collected from human patients between 2011 and 2012.

Results

All Salmonella spp. isolates were subjected to serotyping and antimicrobial susceptibility testing. Isolates displaying phenotypes and antimicrobial susceptibility profiles different from the reference strains were genotipically characterized. Several plasmid-embedded resistance determinants were identified and characterized. Non-typhoidal serotypes were most frequently diagnosed; monophasic Salmonella typhimurium 1,4 [5],12:i- and S. typhimurium represented the most prevalent serovars. Five isolates displayed phenotypes with extremely reduced susceptibility to antimicrobials: we detected multidrug resistance elements belonging to Ambler class A and class C in two non-typhoidal S. enterica serovars, i.e. Rissen and monophasic S. typhimurium 1,4 [5],12:i-, and in one typhoidal serovar, i.e., Paratyphi B. These resistance determinants have been so far almost exclusively associated with non-Salmonella members of the Enterobacteriaceae family. Alarmingly, two colistin resistant Salmonella enteritidis were also found.

Conclusions

This work draws the attention to the still low, but rising, percentage of multidrug resistant Salmonella isolates infecting humans in Italy. Our results suggest that prompt monitoring of Salmonella serovar dissemination and resistance to antimicrobials is highly required.

Keywords

Salmonella Multidrug resistance Humans Epidemiology

Background

Salmonella enterica (S. enterica) consists of more than 2600 different serovars, which, based on different antigens, are subgrouped into typhoidal and non-typhoidal Salmonella (NTS) serovars. These serotypes vary greatly in their virulence, natural reservoirs and susceptibility to antimicrobials [1]. Typhoidal S. enterica serotypes Typhi and Paratyphi A and B infect humans as their exclusive reservoirs, causing outbreaks of life-threatening typhoid fever [2]. Outbreaks of typhoid fever are mainly restricted to low-income countries, while they represent less than 1 % infections in the developed countries. In contrast, non-typhoid salmonellosis usually gives rise to acute but self-resolving gastroenteritis, with no need of antimicrobial therapy; life-threatening invasive infections may occur in vulnerable patients [3].

In 2015, the European food and safety authority (EFSA) reported that the investment of the European Union in Salmonella control measures is yielding noticeable results, with only 20.4 confirmed cases per 100,000 population. Nevertheless, non-typhoidal salmonellosis remains the major cause of foodborne zoonotic outbreaks [4].

The increasing number of antibiotic-resistant Salmonella spp. against first line antimicrobial agents (aminopenicillins, trimethorpim-sulfametoxazole and chloramphenicol) intensified the empirical use of fluoroquinolones and third generation cephalosporins [57]. Noticeably, these classes of antibiotics have been recommended for the treatment of Salmonella infections in animals [8]. In the last years, retail food, livestock and companion animals have been the main sources of NTS transmission [9, 10].

Genetic determinants conferring resistance to beta-lactams and cephalosporins embedded in widely spreading plasmids have been extensively characterized in other Enterobacteriaceae, such as E. coli and K. pneumoniae. The detailed genetic analysis of circulating plasmids helped containing MDR outbreaks [11, 12]. Thus, monitoring serovar distribution and antimicrobial resistance of S. enterica in humans may be important in controlling the infection.

The Microbiology and Virology Unit of the Padua Teaching Hospital, National Reference Centre for enteropathogenic bacteria and antimicrobial resistance epidemiology for the Northeast Italy, has begun in 2009 a strict surveillance of circulating non-pansusceptible Enterobacteriaceae, among which Salmonella spp.

Here we report the phenotypic and genotypic analysis of Salmonella isolates infecting human patients between January 2011 and December 2012 in Northeast Italy, analyzed at the Microbiology and Virology Unit of the Padua Teaching Hospital. We diagnosed and characterized multidrug resistance elements in two non-typhoidal S. enterica serovars, Rissen and monophasic typhimurium, and in one typhoidal serovar, Paratyphi B. The resistance determinants were embedded in plasmids with the ability to transfer between bacterial species. Two S. enterica serotype Enteritidis samples were characterized by colistin resistance.

Methods

Characterization of Salmonella strains: serotyping and antimicrobial susceptibility testing

A total of 734 unique enteropathogenic isolates, obtained exclusively from human patients, were received and characterized by the Microbiology and Virology Unit of the Padua Teaching Hospital. Samples were collected between January 2011 and December 2012, according to the current version of the Declaration of Helsinki. Putative Salmonella containing samples were plated on selective xylose lysine deoxycholate agar (XLD agar, Becton–Dickinson Italia, Milan, Italy) and colonies from pure cultures were characterized using a VITEK® 2 automated system (bioMérieux, Marcy l’Étoile, France). The isolates identified as Salmonella spp. were subjected to serotyping by slide agglutination, according to the Kaufmann-white classification [13].

Antimicrobial susceptibility testing was performed on all confirmed Salmonella isolates, by the disc diffusion (Kirby-Bauer) method according to EUCAST criteria [14]. The following antibiotics (μg/disk) were tested on Mueller–Hinton agar (Difco Laboratories, Detroit, MI), according to Enter-Net specifications: nalidixic acid (30), ampicillin (10), cefotaxime (30), ciprofloxacin (5), chloramphenicol (30), gentamicin (10), kanamycin (30), streptomycin (10), sulphonamide (300), tetracycline (30), trimethoprim (5), ampicillin-clavulanic acid (20-10), cefalotin (30) and sulfamethoxazole-trimethoprim (23.75–1.25) (BD BB™ Sensi-Disk™, Becton–Dickinson Italia, Milan, Italy). Moreover, the disk diffusion test was performed to detect Extended-spectrum beta-lactamases (ESBL) (BD BB™ Sensi-Disk™, Becton–Dickinson Italia, Milan, Italy).

Colistin susceptibility was determined using Sensititre ARIS® 2X (Trek Diagnostic Systems, Thermo Scientific Inc., Milan, Italy). Escherichia coli ATCC25922 and E. coli ATCC35218 were used as control strains.

Identification of ESBL and AmpC determinants: plasmid transfer by transformation and conjugation experiments

Plasmid DNA was obtained from pure bacterial cultures performing phenol/chloroform extraction. Resistance genes (blaTEM, blaSHV, blaCTX-M, and AmpC) were detected by PCR as previously described [15, 16]. Positive PCR products were sequenced in an ABI3130xl sequencer (Applied Biosystems, Thermo Scientific Inc., Milan, Italy) and sequences were aligned to those present in GenBank using BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi).

Plasmids containing PCR-confirmed resistance determinants were introduced into chemo-competent E. coli cells (SCSI, Agilent Technologies Italia, Milan, Italy). Transformants were plated on selective Mueller–Hinton (cefotaxime 2 mg/L or ampicillin 100 mg/L) (Becton–Dickinson & Co., DifcoTM) agar plates. The presence of plasmids was confirmed by PCR targeting the whole sequence of the bla TEM/CTX/CMY gene; PCR products were treated with exosap and fully sequenced (ABI3130xl sequencer, Applied Biosystems). Microbial identification and antimicrobial susceptibility testing on transformants were performed at a VITEK® two automated system (bioMérieux, Marcy l’Étoile, France).

For conjugation experiments, one colony of each donor (S. enterica serovars: Rissen, monophasic S. typhimurium 1,4 [5],12:i- and Paratyphi B) and the recipient strain E. coli J53 (F− met pro Azir Colr) were cultured separately under weak agitation in LB broth at 37 °C. Conjugation was performed incubating different dilutions (from 1:100 to 1:10) of donor suspensions with overnight culture of the recipient strain under low agitation. Mating assays were carried out at room temperature from 1 h to overnight depending on the donor strain. The transconjugants were selected on agar plates containing colistin (8 mg/L) and cefotaxime (2 mg/L) or ampicillin (100 mg/L). Microbial identification and antimicrobial susceptibility testing on transformants and transconjugants were performed by VITEK® two automated system (bioMérieux, Marcy l’Étoile, France).

Plasmid PCR-based replicon typing (PBRT)

All plasmids were analyzed by PCR-based replicon typing (PBRT) targeting the replicons of the major plasmid families occurring in Enterobacteriaceae [17]. Each vector was assigned to a specific Inc group. Plasmid typing was also performed in the obtained transformants and transconjugants.

Amplification and analysis of pmrA and pmrB genes

Bacterial total DNA was obtained by heat shock from pure culture suspension. PmrA and pmrB genes, the major regulators of LPS modifications in S. enterica, were amplified as previously described [18]. PCR amplicons were sequenced by end-primers in an ABI3130xl sequencer (Applied Biosystems, Thermo Scientific Inc., Milan, Italy) and the obtained sequences were compared to the corresponding sequences in the NCBI database (http://www.ncbi.nlm.nih.gov/nucleotide).

Results

Salmonella enterica serotype distribution and antimicrobial susceptibility profiles

The screening of 734 enteropathogenic human specimens yielded identification of 350 S. enterica isolates. On the basis of the Kauffmann-White serotyping, three samples were positive for typhoidal Salmonella strains: two isolates were typed as Salmonella typhi, whereas one belonged to the Paratyphi B serovar. The remaining 99 % samples belonged to different non-typhoidal serovars (NTS). The most common serotypes in the North-eastern part of Italy were monophasic S. typhimurium 1,4 [5],12:i- and S. typhimurium, which were retrieved in approximately 29.5 and 26.5 % samples, respectively (Table 1). The remaining samples belonged predominantly to S. enteritidis, S. panama and S. napoli; other NTS were detected to a minor extent (Table 1).
Table 1

Serotype ditribution of Salmonella enterica isolates diagnosed in this study

Serotype

% isolates/year

S. typhimurium, monophasic 1,4 [5],,12:i-

29.5

S. typhimurium

26.6

S. enteritidis

9.4

S. panama

5.5

S. napoli

3.2

S. muenchen

1.9

S. derby

1.6

S. thomson

1.2

S. rissen

1.2

S. infantis

1

Others

18

Not determined

0.9

Antimicrobial susceptibility testing showed that 38.4 % of isolates were susceptible to all classes of antibiotics. The two Thyphi serovar isolates belonged to this fully susceptible group. The remaining Salmonella isolates displayed different antimicrobial resistance profiles: (i) 12.1 % exhibited reduced susceptibility or resistance to two classes of antimicrobials; (ii) 13.4 % were classified as multidrug-resistant (MDR), i.e. they showed resistance against three or more non-structurally related antimicrobials; (iii) 36.1 % were resistant to ampicillin, streptomycin, sulphonamides and tetracycline (ASSuT resistant pattern). The resistance rate to quinolones and fluoroquinolones (i.e., nalidixic acid and ciprofloxacin) and third generation cephalosporins (i.e., cefotaxime, ceftazidime and ceftriaxone) was relatively low among the isolates. Fluoroquinolones and third generation cephalosporins are the antibiotics most widely used in the treatment of both human and animal infections. In detail, the isolates resistant to nalidixic acid and/or ciprofloxacin were 6 and 0.5 %, respectively. Reduced susceptibility to third generation cephalosporins was detected in 0.9 % isolates. Notably, 0.5 % isolates displayed a resistance phenotype against fourth generation cephalosporins (i.e., cefepime) as well. As reported in other countries, all isolates were fully susceptible to imipenem and meropenem [19, 20].

The presence of extended spectrum beta lactamases (ESBL) and acquired class C cephalosporinases (AmpC) was also investigated by double disk synergy assays. Three isolates displayed an ESBL/AmpC phenotype. These were further characterized at the molecular level to detect plasmid-borne resistance determinants and additional resistance mechanisms.

Molecular analysis of resistance determinants of ESBL/AmpC producing strains

The three isolates that possessed an ESBL/AmpC phenotype belonged to the following serovars: S. paratyphi B, S. rissen and monophasic S. typhimurium 1,4 [5],12:i-. Characterization of resistance determinants was performed on total bacterial DNA extracted as previously described [16, 21]. The major resistance determinants, i.e., bla TEM, bla SHV, plasmidic AmpC genes and bla CTX-M-type, were amplified and sequenced. Genotypic analysis indicated that S. paratyphi B harbored bla TEM-52, S. rissen was positive for bla CMY-2, while monophasic S. typhimurium 1,4 [5],12:i- encoded bla CTX-M-15.

The detected molecular determinants belonged to Ambler Class A and C, which have been previously reported within mobile elements in other members of the Enterobacteriaceae family, responsible for human outbreaks [22]. Therefore, the possible spreading in Salmonella of these resistance determinants through highly diffusible plasmid was investigated.

Plasmid content of the three isolates was analyzed by multiple techniques. Plasmid DNA extractions were analyzed by PCR: the efficient amplification of the selected resistance genes indicated that all determinants conferred plasmid-mediated resistance. For epidemiological tracing purposes, backbones were characterized by PCR amplification of incompatibility groups to determine plasmid replicon typing (PBRT) [17]. This analysis indicated that bla CMY-2 was embedded in an IncA/C plasmid and bla TEM-52 in an IncI1-Iγ plasmid. Plasmid analysis of the bla CTX-M-15-positive monophasic S. typhimurium 1,4 [5],12:i- isolate displayed a double replicon profile, i.e. IncFIIs and IncFIA, indicating the presence of more than one vector or of a backbone with a multi-replicon status.

To confirm plasmid-embedding of the resistance determinants, IncI and IncF plasmids were transformed into E. coli and transformants were analyzed for replicon typing and for the presence of blaCTX-M-15 and blaTEM-52. Transformation experiments demonstrated that blaCTX-M-15 was contained in the IncFIA backbone, while no transformation of the IncFIIs plasmid and blaCMY-2 determinant was obtained. Plasmid size or degradation might account for the absence of transformants.

Many antibiotic resistance plasmids can promote horizontal dissemination of genetic traits among bacteria of different genera through the conjugation process [11]. For this reason, transferability of the resistance determinants was assessed by mating experiments. All three plasmids conjugated successfully: PBRT, along with the presence of the three resistance determinants, was confirmed by PCR in the recipient E. coli J53 strain. The straightforward horizontal transfer of the three backbones suggested that both clonal spread and horizontal plasmid transfer may have contributed to Salmonella resistance dissemination in Salmonella isolates (Table 2).
Table 2

Characteristics of ESBL or AmpC-positive Salmonella isolates and transformed or transconjugated E. coli isolates analyzed in this study

Serovar

Antimicrobial susceptibility testing

ASSuT

PCR

PBRT

AMX (mg/L)

CFPM (mg/L)

CAZ (mg/L)

CTX (mg/L)

FOX (diameter zone)

Additional resistances

  

S. rissen

>8

≤1

>4

≥2

7 mm

GEN, STR, STX, TET

Positive

blaCMY-2

IncA/C

monophasic S. typhimurium (1,4,[5],12:i:-)

>8

≥4

>4

≥2

26 mm

KAN, GEN, STR, STX, TET, TMP

Positive

blaCTX-M-15

IncFIA, IncFIIS

S. Paratyphi B

>8

≥4

>4

≥2

26 mm

nd

Negative

blaTEM-52

I1-Ig

E. coli transformed blaCTX-M-15

>8

≥4

>4

≥2

nd

nd

blaCTX-M-15

IncFIA

E. coli transformed blaTEM-52

>8

≥4

>4

≥2

nd

nd

blaTEM-52

I1-Ig

E. coli J53 blaCMY-2

>8

≤1

>4

≥2

nd

nd

blaCMY-2

IncA/C

E. coli J53 blaCTX-M-15

>8

≥4

>4

≥2

nd

nd

blaCTX-M-15

IncFIA

E. coli J53 blaTEM-52

>8

≥4

>4

≥2

nd

nd

blaTEM-52

I1-Ig

AMX amoxicillin; CFPM cefepime; CAZ ceftazidime; CTX cefotaxime; FOX cefoxitin; KAN kanamycin; GEN gentamicin; STR streptomycin; SMX sulfamethoxazole; TET tetracycline; TMP trimethoprim; nd not detected

Colistin susceptibility testing

Because of the recent uprising rate of colistin resistance reported in Enterobacteriaceae [23, 24], susceptibility to colistin was also evaluated in all Salmonella isolates. Indeed, two isolates of S. enterica serotype Enteritidis, displayed MIC90 higher than 4 μg/mL and were thus considered resistant according to EUCAST breakpoints [14]. As mutations in the pmrAB operon were demonstrated to be involved in Salmonella resistance to colistin and other polymixins [18], pmrA and pmrB genes were amplified and sequenced. PmrA and pmrB nucleotide sequences were identical to those reported for colistin-susceptible isolates: no polymorphic positions with synonymic amino acid substitution, or point nucleotide mutation were detected, suggesting the presence of other resistance mechanisms responsible for the observed reduced susceptibility to colistin [25].

Discussion

Non-typhoidal salmonellosis has not been hitherto considered a major public health risk in developed countries, such as the European Union member states. Up to date, only few epidemiology studies on Salmonella isolates infecting humans has been published so far [19, 26, 27].

In the present study, we presented the Italian epidemiology of Salmonella isolates infecting humans between 2011 and 2012, both in terms of serovar distribution and in terms of antimicrobial resistance patterns.

Our investigation highlighted that pathogenic Salmonella counted for the majority of all enteropathogenic pathogens (47.8 %) diagnosed by our laboratory, National Reference Centre for Enteropathogenic Bacteria for the Northeast Italy. In the 2-year period of the study, more than 11 different serotypes were identified: monophasic S. typhimurium 1,4 [5],12:i:- and S. typhimurium were the prominent circulating serovars, retrieved in almost 30 and 27 % of all samples, respectively. In contrast, the EFSA report on circulating zoonotic agents in 2013 indicated that S. enteritidis was the most prevalent Salmonella serovar detected in human samples [28].

Our epidemiological data are supported by recent works demonstrating that S. typhimurium and monophasic S. typhimurium 1,4 [5],12:i- have extremely high survival rates in the environment [29], can infect a broad range of species [30] and have enhanced their ability to cause salmonellosis in humans [19]. Moreover, these were the most common serotypes diagnosed in serious foodborne salmonellosis outbreaks in both humans and animals in 2012 [31]. Thus, S. typhimurium and monophasic S. typhimurium 1,4 [5],12:i- have to be considered emerging predominant serotypes in humans all around Europe.

In addition, our study pointed out that 61.6 % of analyzed Salmonella isolates were resistant to at least one antibiotic, with 13.3 % of samples classified as multidrug resistant. In accordance with our data, EFSA reported increasing multidrug resistance in Salmonella infecting humans, where monophasic S. typhimurium 1,4 [5],12:i- serotype exhibited the highest rate of multidrug resistance at the European level [32].

Despite the relatively low resistance rate against the clinically important third generation cephalosporins, molecular analysis of strains displaying ESBL/AmpC-producing phenotypes proved that the isolates bore worrisome plasmid-embedded resistance determinants, able to move through bacterial species: AmpC, such as CMY-2, and ESBL, such as TEM-52 and CTX-M-15. The three determinants have been more commonly associated with other members of the Enterobacteriaceae family [33]. Notably, the identified genes have been recently reported in human outbreaks of salmonellosis all around the world [19, 20, 34], associated with other Salmonella serovars and embedded in plasmids distinct from the ones traced in this study.

So far, ESBL have been rarely described in S. paratyphi B at the European level and have been never reported at the Italian level [35, 36]. Moreover, Salmonella serotype Rissen is a widespread contaminant of pigs and pork products [37] and up to date the presence of CMY-like cephalosporinases in this serovar had been reported only in South Korea in 2002 [38, 39]. Our data highlight the possible future spreading of resistance to first line antimicrobials through this serovar.

An additional worrisome feature described here is the detection of two isolates of S. enteritidis displaying resistance to colistin. In Europe, S. enteritidis is reported to be one of the most frequent serotypes diagnosed both in animals and in humans. No other studies detected and characterized, up to date, colistin-resistant isolates belonging to this serovar. Up to 2013, the highest proportions of resistance among S. enteritidis isolates were observed for nalidixic acid (19.5 %) and ampicillin (11.0 %), while resistance to third generation cephalosporins was generally detected at low levels [32]. The spreading of colistin-resistant S. enteritidis could worsen the clinical treatment of life-threatening cases of salmonellosis.

Conclusions

Our results provide an outline of serotype distribution and rising antibiotic resistance among S. enterica causing salmonellosis in humans in Italy. The serotype landscape differs from the one presented by the EFSA reports and deserves to be further monitored.

The described plasmid-embedded resistance determinants circulating in Salmonella serovars should be closely surveilled, as they could possibly become a public health threat, as occurred in the last years for others Enterobacteriaceae, such as K. pneuomoniae [12, 22, 24, 33].

Abbreviations

S. enterica

Salmonella enterica

NTS: 

non-typhoidal Salmonella

EFSA: 

European food and safety authority

E. coli

Escherichia coli

K. pneumoniae

Klebsiella pneumoniae

Azir Colr

sodium azide resistant and colistin resistant

ESBL: 

extended-spectrum beta-lactamases

PBRT: 

PCR-based replicon typing

MDR: 

multidrug resistant

ASSuT: 

ampicillin, streptomycin, sulfonamides, and tetracycline

Declarations

Authors’ contributions

IF carried out the genotypic assays, performed the analysis and interpretation of data and drafted the manuscript, SB performed the phenotypic analysis, EDC performed the phenotypic analysis and data collection, SNR conceived of the study, participated in its design and coordination and revised the manuscript; GP participated in the study coordination. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by The University of Padua and The Italian Ministry of Education, Universities and Research.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Molecular Medicine, University of Padua
(2)
Microbiology and Virology Unit, Padua Teaching Hospital

References

  1. Gal-Mor O, Boyle EC, Grassl GA. Same species, different diseases: how and why typhoidal and non-typhoidal Salmonella enterica serovars differ. Front Microbiol. 2014;5:391.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Buckle GC, Walker CL, Black RE. Typhoid fever and paratyphoid fever: systematic review to estimate global morbidity and mortality for 2010. J Glob Health. 2012;2(1):010401.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Gordon MA. Invasive nontyphoidal Salmonella disease: epidemiology, pathogenesis and diagnosis. Curr Opin Infect Dis. 2011;24(5):484–9.View ArticlePubMedPubMed CentralGoogle Scholar
  4. The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2013. EFSA Journal 2015;13(1):3991.Google Scholar
  5. Collignon P, Powers JH, Chiller TM, Aidara-Kane A, Aarestrup FM. World Health Organization ranking of antimicrobials according to their importance in human medicine: a critical step for developing risk management strategies for the use of antimicrobials in food production animals. Clin Infect Dis. 2009;49(1):132–41.View ArticlePubMedGoogle Scholar
  6. Van TT, Nguyen HN, Smooker PM, Coloe PJ. The antibiotic resistance characteristics of non-typhoidal Salmonella enterica isolated from food-producing animals, retail meat and humans in South East Asia. Int J Food Microbiol. 2012;154(3):98–106.View ArticlePubMedGoogle Scholar
  7. World Health Organization Advisory Group on Integrated Surveillance of Antimicrobial Resistance. Critically important antimicrobials for human medicine. 3rd Revision. World Health Organization; 2012.Google Scholar
  8. Veterinary SAGoAotCfMPf. Reflection paper on the use of third and fourth generation cephalosporins in food producing animals in the European Union: development of resistance and impact on human and animal health. J Vet Pharmacol Ther. 2009;32(6):515–33.View ArticleGoogle Scholar
  9. Fashae K, Ogunsola F, Aarestrup FM, Hendriksen RS. Antimicrobial susceptibility and serovars of Salmonella from chickens and humans in Ibadan. Nigeria. J Infect Dev Ctries. 2010;4(8):484–94.PubMedGoogle Scholar
  10. Foley SL, Lynne AM. Food animal-associated Salmonella challenges: pathogenicity and antimicrobial resistance. J Anim Sci. 2008;86(14 Suppl):E173–87.PubMedGoogle Scholar
  11. Frasson I, Lavezzo E, Franchin E, Toppo S, Barzon L, Cavallaro A, Richter SN, Palu G. Antimicrobial treatment and containment measures for an extremely drug-resistant Klebsiella pneumoniae ST101 isolate carrying pKPN101-IT, a novel fully sequenced bla(KPC-2) plasmid. J Clin Microbiol. 2012;50(11):3768–72.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Nordmann P, Poirel L. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin Microbiol Infect. 2014;20(9):821–30.View ArticlePubMedGoogle Scholar
  13. Grimont PAD, Weill FX. Antigenic formulae of the Salmonella serovars. In : WHO collaborating centre for reference and research on Salmonella. 9th ed. Paris: Institut Pasteur; 2007.Google Scholar
  14. Breakpoint tables for interpretation of MICs and zone diameters.Google Scholar
  15. Perez-Perez FJ, Hanson ND. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol. 2002;40(6):2153–62.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Richter SN, Frasson I, Franchin E, Bergo C, Lavezzo E, Barzon L, Cavallaro A, Palu G. KPC-mediated resistance in Klebsiella pneumoniae in two hospitals in Padua, Italy, June 2009-December: massive spreading of a KPC-3-encoding plasmid and involvement of non-intensive care units. Gut Pathog. 2011;4(1):7.View ArticleGoogle Scholar
  17. Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. Identification of plasmids by PCR-based replicon typing. J Microbiol Method. 2005;63(3):219–28.View ArticleGoogle Scholar
  18. Sun S, Negrea A, Rhen M, Andersson DI. Genetic analysis of colistin resistance in Salmonella enterica serovar typhimurium. Antimicrob Agents Chemother. 2009;53(6):2298–305.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Ceyssens PJ, Mattheus W, Vanhoof R, Bertrand S. Trends in serotype distribution and antimicrobial susceptibility in Salmonella enterica isolates from humans in Belgium, 2009 to 2013. Antimicrob Agents Chemother. 2015;59(1):544–52.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Kariuki S, Okoro C, Kiiru J, Njoroge S, Omuse G, Langridge G, Kingsley RA, Dougan G, Revathi G. Ceftriaxone-resistant Salmonella enterica serotype typhimurium sequence type 313 from Kenyan patients is associated with the blaCTX-M-15 gene on a novel IncHI2 plasmid. Antimicrob Agents Chemother. 2015;59(6):3133–9.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Bartolini A, Frasson I, Cavallaro A, Richter SN, Palu G. Comparison of phenotypic methods for the detection of carbapenem non-susceptible Enterobacteriaceae. Gut Pathog. 2014;6:13.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Nordmann P. Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. Med Mal Infect. 2014;44(2):51–6.View ArticlePubMedGoogle Scholar
  23. Catry B, Cavaleri M, Baptiste K, Grave K, Grein K, Holm A, Jukes H, Liebana E, Lopez Navas A, Mackay D, et al. Use of colistin-containing products within the European Union and European Economic Area (EU/EEA): development of resistance in animals and possible impact on human and animal health. Int J Antimicrob Agents. 2015;46(3):297–306.View ArticlePubMedGoogle Scholar
  24. Giske CG. Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin. Clin Microbiol Infect. 2015;21(10):899–905.View ArticlePubMedGoogle Scholar
  25. Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol. 2014;5:643.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Olaitan AO, Dia NM, Gautret P, Benkouiten S, Belhouchat K, Drali T, Parola P, Brouqui P, Memish Z, Raoult D, et al. Acquisition of extended-spectrum cephalosporin- and colistin-resistant Salmonella enterica subsp. enterica serotype Newport by pilgrims during Hajj. Int J Antimicrob Agents. 2015;45(6):600–4.View ArticlePubMedGoogle Scholar
  27. Campos MJ, Palomo G, Hormeno L, Herrera-Leon S, Dominguez L, Vadillo S, Piriz S, Quesada A. Prevalence of quinolone resistance determinants in non-typhoidal Salmonella isolates from human origin in Extremadura, Spain. Diagn Microbiol Infect Dis. 2014;79(1):64–9.View ArticlePubMedGoogle Scholar
  28. EFSA SRo. The European Union Summary Report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2012. EFSA J. 2014;12(3):3590014.Google Scholar
  29. Habimana O, Nesse LL, Moretro T, Berg K, Heir E, Vestby LK, Langsrud S. The persistence of Salmonella following desiccation under feed processing environmental conditions: a subject of relevance. Lett Appl Microbiol. 2014;59(5):464–70.View ArticlePubMedGoogle Scholar
  30. Rabsch W, Andrews HL, Kingsley RA, Prager R, Tschape H, Adams LG, Baumler AJ. Salmonella enterica serotype typhimurium and its host-adapted variants. Infect Immun. 2002;70(5):2249–55.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Clemente L, Manageiro V, Jones-Dias D, Correia I, Themudo P, Albuquerque T, Geraldes M, Matos F, Almendra C, Ferreira E, et al. Antimicrobial susceptibility and oxymino-beta-lactam resistance mechanisms in Salmonella enterica and Escherichia coli isolates from different animal sources. Res Microbiol. 2015;166(7):574–83.View ArticlePubMedGoogle Scholar
  32. EFSA. EU Summary Report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2013. EFSA J. 2015;3(2):4036.Google Scholar
  33. Tangden T, Giske CG. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Intern Med. 2015;277(5):501–12.View ArticlePubMedGoogle Scholar
  34. de Toro M, Garcia P, Rodriguez I, Rojo-Bezares B, Helmuth R, Saenz Y, Rodicio MR, Guerra B, Torres C. Characterisation of plasmids implicated in the mobilisation of extended-spectrum and AmpC beta-lactamase genes in clinical Salmonella enterica isolates and temporal stability of the resistance genotype. Int J Antimicrob Agents. 2013;42(2):167–72.View ArticlePubMedGoogle Scholar
  35. Cloeckaert A, Praud K, Doublet B, Bertini A, Carattoli A, Butaye P, Imberechts H, Bertrand S, Collard JM, Arlet G, et al. Dissemination of an extended-spectrum-beta-lactamase blaTEM-52 gene-carrying IncI1 plasmid in various Salmonella enterica serovars isolated from poultry and humans in Belgium and France between 2001 and 2005. Antimicrob Agents Chemother. 2007;51(5):1872–5.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Hasman H, Mevius D, Veldman K, Olesen I, Aarestrup FM. beta-Lactamases among extended-spectrum beta-lactamase (ESBL)-resistant Salmonella from poultry, poultry products and human patients in The Netherlands. J Antimicrob Chemother. 2005;56(1):115–21.View ArticlePubMedGoogle Scholar
  37. Garcia-Fierro R, Montero I, Bances M, Gonzalez-Hevia MA, Rodicio MR. Antimicrobial Drug resistance and molecular typing of Salmonella enterica serovar rissen from different sources. Microb Drug Resist. 2015;22:211.View ArticlePubMedGoogle Scholar
  38. Garcia-Fierro R, Montero I, Bances M, Gonzalez-Hevia MA, Rodicio MR. Antimicrobial drug resistance and molecular typing of Salmonella enterica serovar rissen from different sources. Microb Drug Resist. 2016;22:211.View ArticlePubMedGoogle Scholar
  39. Song W, Kim JS, Kim HS, Park MJ, Lee KM. Appearance of Salmonella enterica isolates producing plasmid-mediated AmpC beta-lactamase, CMY-2, South Korea. Diagn Microbiol Infect Dis. 2005;52(4):281–4.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s) 2016